BioTech: A Prescription for Progression - Market Research on Biomoda, Inc. and Harbor BioSciences, Inc.
15 Giugno 2011 - 3:00PM
Marketwired
Today, www.GlobalEquityReporter.com announced its research report
highlighting Biomoda, Inc. (OTCBB: BMOD) and Harbor BioSciences,
Inc. (OTCBB: HRBR). Full report download is available at
www.GlobalEquityReporter.com/access.php.
While it is thought that the recent healthcare reform
legislation will negatively affect industry profitability over the
next few years, new innovations within the healthcare field have
maintained an influx of new interest to the industry. Combining
medical technology with human touch, the healthcare industry
diagnoses, treats, and administers care around the clock --
responding to the needs of millions of people. Pharmaceuticals
should remain one of the widest-margin industries, with prospects
enhanced by demographic growth in the elderly and new drugs
stemming from discoveries in genomics and biotechnology. Longer
term, it is expected that a wider acceptance of biomarker research
and genetic-targeted clinical studies to help limit expense. It is
viewed that therapeutics for cancer and infectious diseases and
autoimmune and inflammatory treatments are primary growth
areas.
Global Equity is reporting on Biomoda, Inc. as a
development-stage company. It is an invitro diagnostics company,
which develops, assays, or tests, to detect cancer. The assays are
performed in clinical reference laboratories using body-fluid
samples. The technology is based on a porphyrin molecule that has
an affinity to bind with cancer cells and cause them to fluoresce
red under ultraviolet light. The porphyrin molecule is easy to
obtain, manufacture and use. The full report and profile Biomoda,
Inc. (OTCBB: BMOD) is available here:
www.GlobalEquityReporter.com/get.PDF.1824.php.
Global Equity Reporter brings Harbor BioSciences, Inc. to light
as a clinical-stage pharmaceutical company, engaged in the
discovery and development of products for the treatment of diseases
related to aging. The Company is primarily focused on the
development of a series of steroid hormone analogs that are derived
from the human adrenal metabolome. The full report and profile on
Harbor BioSciences, Inc. (OTCBB: HRBR) is available here:
www.GlobalEquityReporter.com/get.PDF.1937.php.
About Global Equity Reporter Global Equity Reporter is a premier
source for microcap research -- providing a wide range of due
diligence and investment insight on stocks all over the market
Global Equity Reporter's primary focus is to alert our valued
subscribers to small cap and microcap companies poised for
explosive movement in the market. As every investor knows, timing
in the market is critical, and that's where Global Equity Reporter
delivers.
Contact: Alexander Griffin Email Contact
www.GlobalEquityReporter.com
Grafico Azioni Harbor Diversified (CE) (USOTC:HRBR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Harbor Diversified (CE) (USOTC:HRBR)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Harbor Diversified Inc (CE) (OTCMarkets): 0 articoli recenti
Più Global Equity Reporter Articoli Notizie